FDA grants breakthrough therapy status to LSD formula for generalized anxiety disorder by Mind Medicine Inc.

The US Food and Drug Administration has granted breakthrough therapy status to an LSD formula for treating generalized anxiety disorder. Developed by Mind Medicine Inc., the drug's initial study showed that a single dose could provide lasting relief. Although it must still go through standard FDA approval and Phase 3 clinical trials, the breakthrough designation indicates a promising development for addressing an unmet medical need.